REAL-LIFE PERSISTENCE OF BUDESONIDE/FORMOTEROL SPIROMAX FOR THE MANAGEMENT OF ASTHMA AND COPD IN THE UK

Author(s)

Benhaddi H1, Van Der Tol M2, Price D3, Batsiou M4, Ariely R5
1TEVA Pharma, Brussels, Belgium, 2TEVA Pharma, Amsterdam, The Netherlands, 3Research In Real Life, Singapore, Singapore, 4Research In Real Life, Cambridge, UK, 5TEVA Pharma, Malvern, PA, USA

OBJECTIVES:  

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PRS5

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×